Abstract Number: 2805 • 2016 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Background/Purpose: Lupus nephritis (LN) complicates 60% of systemic lupus erythematosus (SLE) patients within 5 years of diagnosis. Glucocorticoids and disease modifying immunosuppressive drugs (IS) are…Abstract Number: 2806 • 2016 ACR/ARHP Annual Meeting
A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
Background/Purpose: Type I interferon has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about its role in other…Abstract Number: 2807 • 2016 ACR/ARHP Annual Meeting
Skin and Muscle Sodium Concentrations in Patients with Systemic Lupus Erythematosus: A Proof of Concept Study
Background/Purpose: Results: SLE (n=7) Controls (n=8) p-value Age 41 (32-56) 34 (28-47) 0.42 Female n (%) 6 (86%) 7 (88%) 0.73 Systolic blood…Abstract Number: 2808 • 2016 ACR/ARHP Annual Meeting
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…Abstract Number: 2809 • 2016 ACR/ARHP Annual Meeting
Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories
Background/Purpose: Serological positivity defined by presence of anti-nuclear antibodies (ANA) is frequently used in interventional lupus trials as an inclusion criterion and longitudinal biomarker. As such,…Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…Abstract Number: 2812 • 2016 ACR/ARHP Annual Meeting
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
Background/Purpose: Clinical trials of patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) can be confounded by difficulties in engaging patients. Identifying factors of…Abstract Number: 2813 • 2016 ACR/ARHP Annual Meeting
Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at elevated risk for lupus nephritis and ultimately renal failure. While some risk factors for renal…Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…Abstract Number: 2816 • 2016 ACR/ARHP Annual Meeting
Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide range of clinical manifestations. Production of autoantibodies is a hallmark of SLE and…Abstract Number: 2817 • 2016 ACR/ARHP Annual Meeting
Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous disease, with a considerably variability of disease expression among patients. There have been several attempts to classify…Abstract Number: 2818 • 2016 ACR/ARHP Annual Meeting
High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE
Background/Purpose: Patients with SLE have a broad clinical and immunological phenotype in which multiple immune pathways may be sequentially or simultaneously activated. No reliable biomarkers…Abstract Number: 2819 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of autoantibodies. Among the complications of SLE, neuropsychiatric manifestations (NPSLE) can…
ACR Meeting Abstracts